Impact of anti-CD20 monoclonal antibodies on serologic response to
Por um escritor misterioso
Descrição
A third anti-SARS-CoV-2 mRNA dose does not overcome the pejorative impact of anti-CD20 therapy and/or low immunoglobulin levels in patients with lymphoma or chronic lymphocytic leukemia
Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy
Anti-CD20 therapies for multiple sclerosis: current status and future perspectives
Frontiers IgG4 Autoantibodies in Organ-Specific Autoimmunopathies: Reviewing Class Switching, Antibody-Producing Cells, and Specific Immunotherapies
Neutralizing antibody against anti–SARS-CoV-2 vaccination
Tumor-reactive antibodies evolve from non-binding and autoreactive precursors - ScienceDirect
Synergistic anti-tumor therapy by a comb-like multifunctional antibody nanoarray with exceptionally potent activity
Long-term immunological consequences of anti-CD20 therapies on humoral responses to COVID-19 vaccines in multiple sclerosis: an observational study - Tobias Moser, Ciara O'Sullivan, Ferdinand Otto, Wolfgang Hitzl, Georg Pilz, Kerstin Schwenker, Cornelia
Overview of therapeutic monoclonal antibodies - UpToDate
de
por adulto (o preço varia de acordo com o tamanho do grupo)
